Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-11-18 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于部分高级管理人员增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholdings by certain senior management personnel of the company. It details the names, positions, shareholding before and after the increase, the method of purchase, and compliance with relevant laws. There is no financial report, earnings data, or management discussion of financial results. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on share transactions by directors, confirming it is not a full financial report or other type of filing.
2020-11-18 Chinese
关于非公开发行股票申请获得中国证监会受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the acceptance of a non-public stock issuance application by the China Securities Regulatory Commission. It states that the application materials have been accepted for review but the approval is still pending. The document is brief (464 characters) and does not contain financial statements or detailed financial data. It is an update on a capital raising process, specifically about the regulatory acceptance of the application, not the actual issuance or detailed financing report. Therefore, it fits best under Capital/Financing Update (CAP).
2020-11-12 Chinese
2020年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 second extraordinary general meeting of shareholders of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes voting results on various proposals, meeting attendance, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder voting outcomes and meeting procedural details rather than presenting financial statements or management discussion. The document is not a full annual or interim report, nor is it a call transcript or earnings release. It is not a proxy solicitation or a remuneration report. The key feature is the official disclosure of voting results from a shareholders' meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2020-10-30 Chinese
2020年第二次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2020 second extraordinary general meeting of shareholders of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the legal compliance of the meeting procedures, qualifications of attendees, and the validity of the resolutions passed. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is a formal legal opinion related to a shareholders' meeting and the voting results of that meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms their legality and validity.
2020-10-30 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2020 年第三季度报告正文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2020 Third Quarter Report." It contains detailed financial data, including assets, liabilities, income, cash flows, shareholder information, and notes on significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (the third quarter of 2020) clearly indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2020
2020-10-22 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2020 年第三季度报告全文" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2020 Third Quarter Report Full Text." It contains detailed financial data for the third quarter of 2020, including assets, liabilities, income, profit, cash flows, shareholder information, and notes on significant events during the quarter. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) confirms this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-10-22 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.